SPONSOR
Glaukos Corporation
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 2, Phase 2, Phase 3
Glaukos Corporation is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Glaucoma, Persistent Corneal Epithelial Defect.
The trial portfolio spans Phase 3, Phase 2, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Glaukos Corporation
How many clinical trials has Glaukos Corporation sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Glaukos Corporation, of which 3 are actively recruiting participants. These trials cover conditions including Glaucoma, Persistent Corneal Epithelial Defect. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Glaukos Corporation research focus on?
Glaukos Corporation clinical trials span Glaucoma, Persistent Corneal Epithelial Defect. The research pipeline includes Phase 3, Phase 2, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Glaukos Corporation clinical trial?
To participate in a Glaukos Corporation trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Glaukos Corporation trials with current recruitment status updated daily.
Clinical Trials by Glaukos Corporation
NCT07495852 Phase 3
Recruiting
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaucoma
NCT05966493 Phase 2
Recruiting
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
Persistent Corneal Epithelial Defect
NCT07075718 Phase 2, Phase 3
Recruiting
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Glaucoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology